These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 30513017)
21. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. van Os W; Zeitlinger M J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805 [TBL] [Abstract][Full Text] [Related]
22. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. Rodvold KA J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709 [TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172 [TBL] [Abstract][Full Text] [Related]
24. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial. LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270 [TBL] [Abstract][Full Text] [Related]
25. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria. Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291 [TBL] [Abstract][Full Text] [Related]
27. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651 [TBL] [Abstract][Full Text] [Related]
28. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. Wicha WW; Craig WA; Andes D J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706 [TBL] [Abstract][Full Text] [Related]
29. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995 [TBL] [Abstract][Full Text] [Related]
30. Clinical Utility of Lefamulin: If Not Now, When? Mercuro NJ; Veve MP Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786 [TBL] [Abstract][Full Text] [Related]
31. Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia. Felix TM; Karpa K Am Fam Physician; 2020 Sep; 102(6):373-374. PubMed ID: 32931220 [No Abstract] [Full Text] [Related]
32. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial. McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142 [TBL] [Abstract][Full Text] [Related]
37. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326 [TBL] [Abstract][Full Text] [Related]
38. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239 [TBL] [Abstract][Full Text] [Related]
40. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]